AGN-151607-DP

Phase 2Small molecule

AbbVie

AGN-151607-DP is one of 46 small molecule programs targeting Ventral Hernia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ventral HerniaActive, not recruiting

Essential TremorRecruiting

Ventral HerniaPhase 2

Active, not recruiting

Essential TremorPhase 2

Recruiting

Competition

Competitive Landscape

46 competitors in Essential Tremor

#DrugCompanyPhaseTrials

Namenda

AbbVie

Approved

1 2

Epidiolex

Jazz Pharmaceuticals

Approved

—3

Marinol

Alnylam Pharmaceuticals

Approved

—4

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 5

Topamax

Mirapex

1 7

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Xyrem

1 9

Zonegran

AAzurity Pharmaceuticals

Phase 2

2 10

Fycompa

CCatalyst Biosciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Essential Tremor

NCT07673107

Q2 2030

Phase 2Recruiting

Ventral Hernia

NCT07226791

Clinical

Trials by Indication[1]

Ventral Hernia1 trial

A Phase 2 Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique, in Subjects Undergoing Open Abdominal Ventral Hernia Repair

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT07226791·200 enrolled

Essential Tremor1 trial

A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT07673107·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AGN-151607-DP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AGN-151607-DP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AGN-151607-DP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AbbVie

AGN-151607-DP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2030

Trials by Indication[1]

Ventral Hernia1 trial

Essential Tremor1 trial

References

Drug Info

Quick Facts

Related News